Welcome to our dedicated page for Revium Recovery SEC filings (Ticker: RVRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Revium Recovery Inc’s biotechnology disclosures are packed with nanoparticle pharmacokinetics, clinical trial protocols, and licensing clauses—details crucial to gauging future breakthroughs yet buried in hundreds of pages. Finding when executives purchase shares before a trial read-out or pinpointing dilution risk from a new financing round shouldn’t require a PhD.
Stock Titan makes sense of it all. Our AI-powered summaries break down every Revium Recovery SEC filing, turning dense 10-K annual reports into plain-English briefs and flagging the paragraphs that discuss pivotal trials. Track Revium Recovery insider trading Form 4 transactions in real time, see each Revium Recovery quarterly earnings report 10-Q filing alongside year-over-year R&D spend, and get an alert the moment an 8-K material event is posted—complete with context and trend charts.
- Form 4 insider transactions real-time: Know within minutes when leadership buys or sells.
- Annual report 10-K simplified: AI extracts pipeline status, cash runway, and licensing revenue.
- Proxy statement executive compensation: Understand alignment of pay with scientific milestones.
Whether you’re comparing quarter-over-quarter burn rates, monitoring executive stock transactions Form 4, or simply understanding Revium Recovery SEC documents with AI, Stock Titan delivers the clarity professionals need. Save hours, surface what moves the valuation, and never miss a Revium Recovery earnings report filing analysis again.
Revium Rx (RVRC) filed an amended S-1 registering a self-underwritten primary offering of 1,562,500 Units at a fixed public offering price of $3.20 per Unit (each Unit = two shares + one warrant) and a resale registration for up to 37,625,790 shares by selling stockholders. The Company expects $4,400,000 in net proceeds if all Units sell and no IPO warrants are exercised, and proposes to allocate approximately 55% (~$2.42M) to advance Nano-Mupirocin, 25% (~$1.1M) to Nano-ARB work, and 20% (~$880k) to G&A.
The filing discloses material risks including a history of losses, substantial future funding needs, potential dilution from existing warrants and resale shares, penny-stock trading restrictions, dependence on key officers, IP and regulatory risks for its nanoformulations, and operational exposure from Israeli geopolitical instability. The document also states an existing Non-Clinical Evaluation Agreement with NIAID and exclusive license rights for LPLT vaccine technology, with a SARS-CoV-2 challenge study expected to resume in Q4 2025 and conclude in Q1 2026.
FAQ
What is the current stock price of Revium Recovery (RVRC)?
What is the market cap of Revium Recovery (RVRC)?
